How Whole Systems Thinking Will Transform the Pharma Supply Chain

Time: 3:10 pm - 3:30 pm

Date: 30 April 2019

30-april-2019 15:10 30-april-2019 15:30 Europe/London How Whole Systems Thinking Will Transform the Pharma Supply Chain

In 2006, the United States Government Accountability Office (US GAO) issued a report, GAO-07-49, highlighting historical attrition rates in drug development. It recounted that of every 250 development candidates entering preclinical development, only five made it into the clinic. Of that five, only one would be approved by the regulators. Four were destined to fail…. Read more »

Making Pharmaceuticals

Synopsis

In 2006, the United States Government Accountability Office (US GAO) issued a report, GAO-07-49, highlighting historical attrition rates in drug development. It recounted that of every 250 development candidates entering preclinical development, only five made it into the clinic. Of that five, only one would be approved by the regulators. Four were destined to fail.

Those alarming statistics were confirmed in 2012, when Tuft’s University reported similar figures, with a worsening for the clinic, as five out of six clinical trials were likely to go down. This article contends this is clear evidence that the current drug development system is broken and needs a completely different approach.

An alternative approach will therefore be presented, based on Whole Systems Thinking, whereby the incumbent system is turned on its head, with health care professionals co-developing drugs from inception and predictive methods of prototyping employed, pre-clinic and during clinical trials, to maximum effect. This approach has the potential to be transformational, as a far greater number of compounds are likely to bridge the valley of death to reach commercial success.

Speakers

« Back